



A physician's guide to Precise™ Oncology Solutions

Helping you find treatment clarity in cancer complexity



As an expert in cancer care,
you rely on genetic insights
to formulate the best
treatment options
for your patients



Precise Oncology Solutions provides a streamlined testing experience that gives you the ability to receive results for comprehensive germline testing, tumor profiling and companion diagnostic options, including HRD testing[†] with one order.



One order




Interpretative
accuracy



Comprehensive
results

Treating cancer is complex, but your testing experience doesn't need to be

- Save time with a streamlined ordering process for multiple tests
- Companion diagnostic treatment eligibility enables more treatment options for appropriate patients
- Fast delivery of results through our secure portal
- Summary sheet to help clarify actionable results after all tests are completed
- Eliminate discordant results with Myriad Genetics' interpretive accuracy



[†] For patients with ovarian cancer

[‡] Precise™ Tumor is powered by Intermountain Precision Genomics®, a service of Intermountain® Healthcare

Precise Oncology Solutions allows you to order both germline and somatic testing in one seamless experience



These genetic insights will not only help you make treatment decisions but can also aid your network of colleagues as they interact with and assess your patient for additional care.

Somatic testing alone can have some limitations including:



Unknown variants




Limited tumor tissue




Potentially missed large rearrangements

The combination of somatic AND germline testing can help determine comprehensive treatment options, earlier and faster:



1. Robson M, et al. N Engl J Med. 2018;37:523-533.
2. Golan T, et al. N Engl J Med. 2019;381(4): 317-327.
3. Moore KN, et al. N Engl J Med. 2018;379(26):2495-2505.
4. deBono J, et al. N Engl J Med. 2020;282:2091-2102.



Less time, less effort,
more actionable results

How to Order:



Fill out a test request form in the Myriad Genetics provider portal



Submit a blood or saliva sample for your patient's germline test



Our laboratory processing staff will contact your pathology partner directly to obtain the tumor sample for any somatic or HRD testing that is ordered

Each test result is reported out as it becomes available in the portal, and you will be provided with an easy-to-interpret summary sheet for all tests ordered for each patient.


Precise™

Oncology Solutions


- Tumor blocks sent to a single location
- No discordant results
- Identify patients who may benefit from PARP inhibitor therapy
- Identify patients who may qualify for clinical trials
- Optional participation in Molecular Tumor Board
- PD-L1 available as an add-on (if Precise™ Tumor testing is ordered)
- Optional enrollment in treatment registry (if Precise Tumor testing is ordered)

Clarity starts here

Upon completion of all tests, you will receive a high-level summary sheet*, signaling all results are in, and allowing you to minimize your time in report review.



FILE COPY
CONFIDENTIAL



Summary Sheet

HEALTHCARE PROVIDER(S)
 Ordering HCP, MD
 Receiving HCP, MD
 Pathologist, MD

INSTITUTION

PATIENT
 Name: Pt Last Name, Pt First Name
 Date of Birth: Mar 06, 1978
 Patient ID: Patient id
 Gender: Female
 Cancer Site: Ovarian, Left Ovary

GERMLINE STATUS

Integrated BRACAnalysis
 MyRisk Update

Accession #: 00000000-BLD
 Accession #: 00000000-BLD

For full details on germline test results, please see the individual test report(s).

MYRIAD HRD STATUS

Myriad MyChoice CDx

Accession #: 00000000-BLD

For full details on Myriad MyChoice CDx test results, please see the test report.

TUMOR MOLECULAR PROFILING

Precise Tumor with PD-L1

Accession #: 00000000-BLD

Original Report: Jan 11, 2021
 Last Report: Jan, 13, 2021

This list of genes is not intended to be representative of all findings that are included on the Precise Tumor report. For a full list of findings and genes analyzed, please see the individual test report to verify this information.

POTENTIALLY SIGNIFICANT FINDINGS

Tier IA	Tier IB	Tier IIC	Tier IID
KRAS	BRAF	NTRK1/2/3	ATM
	NBN	TERT	CBFB
	PIK3CA	SDHC	

BIOMARKER	LEVEL
TMB	High
MSI	Stable
PD-L1	Negative

12 CLINICAL TRIALS
 For details on clinical trials, please see the report

BIOMARKERS TESTED WITH NO CLINICALLY SIGNIFICANT FINDING

MSH2	BARD1	BRCA2	RAD51C	RAD51D	MLH1	BRCA1	PTEN	TP53	MSH3
EPCAM	PMS2								

This summary is for informational purposes only. It is not a test result, and it should not be used for medical management. Please review the associated test result(s) to verify this information and for medical management purposes. If an amended report is issued for an associated test result, this summary may not be updated. For information on clinical trial eligibility, please see the Precise Tumor report.

Summary of key findings for all tests ordered on one sheet

Quickly find the status of relevant biomarkers based on your patient's cancer type

Know how many clinical trials may be available for your patient

See potentially significant findings first to identify the most relevant parts of each test report



Talk to your Myriad account manager to get enrolled in the new Myriad Genetics provider portal and start your new testing experience now!

*Summary sheet includes information from both FDA-approved and non-FDA-approved tests and will be reflective of the specific tests ordered for each patient.